



PARTICLE SCIENCES

DRUG DEVELOPMENT SERVICES

PRESS RELEASE

Particle Sciences, Inc. and Dow Corning Corporation Cooperate to Develop New Product Technology

Bethlehem, PA October 6, 2009 - [Particle Sciences](#) has announced today that they have been engaged by Dow Corning to develop technology for a key Dow Corning product development project. Bruce Frank, Director of Project Management for Particle Sciences remarked, "This is a little outside our normal focus of pharmaceutical development but the technological approach is perfectly analogous. We expect to provide a novel and robust solution that allows Dow Corning to develop a product that will benefit its customers." Andrew Loxley, Director, New Technologies for Particle Sciences added that "Particle Sciences is leveraging its extensive experience and expertise to evaluate a number of technologies deemed suitable for the complex performance characteristics of this particular product. Developing a suitable approach will lead directly to a fast-track scale-up and technology transfer program to commercialize this product." Additional terms of the agreement have not been released.

About Dow Corning

[Dow Corning](#) Corporation provides performance-enhancing solutions to serve the diverse needs of more than 25,000 customers worldwide. A global leader in [silicones](#), silicon-based technology and innovation, Dow Corning offers more than 7,000 products and services via the company's Dow Corning® and XIAMETER® brands. Dow Corning is a joint venture equally owned by The Dow Chemical Company and Corning, Incorporated. More than half of Dow Corning's annual sales are outside the United States.

About Particle Sciences

Particle Sciences is a Bethlehem, PA based Contract Formulation and Analytical Services company that focuses on the Pharmaceutical Industry. Their services include the development of novel encapsulation and drug delivery technologies including drug-device combination products, nanoparticle production and characterization, cGMP analytical services and clinical drug product manufacturing for Phase I and II clinical trials. Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861-4701 for information.

Maureen Cochran 610-861-4701